Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesIssue 543

Structured Blood Glucose Testing with Pattern Analysis Improves Blood Sugars

Structured self-monitored blood glucose with pattern analysis has been associated with greater reductions in A1c. It also requires less testing than the standard approach, and promotes more timely and aggressive treatment changes in poorly controlled, non-insulin-treated patients with Type 2 diabetes, according to study results....

Advertisement

Lead author Pamela Kushner, MD, Long Beach, California, stated that, the 12-month, randomized, controlled, multicentre study assessed the effect of structured testing on results of HbA1c.

In all, 483 insulin-naïve subjects were selected based on their poorly controlled (HbA1c >= 7.5%) Type 2 diabetes. The patients were randomized into 2 divisions: usual care in the Active Control Group or usual care with a minimum quarterly use of structured testing with pattern analysis in the Structured Testing Group. All patients were instructed to monitor their blood glucose as usual, based on their healthcare providers' instructions, but Structured Testing Group members were also instructed on recording blood glucose levels, food eaten, and energy levels as well as pattern analysis. Patients in the Structured Testing Group had to complete a 3-day structured testing session, involving 7 tests per day, prior to quarterly visits, and all patients were seen at least once quarterly as well as performing self-monitored blood glucose between study visits.

Both groups did have significant reductions in HbA1c over the trial period, but an intent-to-treat analysis showed greater reductions in the Structured Testing Group than in the Active Control Group (-1.2% vs. -0.9%, P =.04). Furthermore, mean daily blood glucose tests were significantly lower for the Structured Testing Group than the Active Control Group at 6, 9, and 12 months (P =.007,.001, and.0004, respectively), reported Dr. Kushner.

Structured Testing Group healthcare providers were 31% more likely to recommend at least 1 medical treatment change at the first treatment visit 1 month post baseline, 33% were more likely to recommend lifestyle adjustments, and 33% were more likely to recommend a combination of the two (P =.0001). Subjects who received this treatment change at the first visit were able to achieve a significantly larger HbA1c reduction than those who did not receive a recommendation. "And they were significantly less likely to have clinical inertia," Dr. Kushner added.

Ultimately, the researchers concluded that "early treatment changes are linked to significant glycemic improvement over 12 months, and may be a major reason why subjects in the Structured Testing Group evidenced a significantly greater reduction in HbA1c than Active Control Group subjects." Dr. Kushner also noted that patients and physicians reported that they "liked having the ability to track patterns in their results based on their behavior."

For a copy of the form used by the patients for the pattern analysis see our Tool for Your Practice, 360 View -- A Simple Blood Glucose Analysis System (PDF).

[Structured Blood Glucose Testing Leads to Improvements in HbA1c in Patients With Poorly Controlled, Non-Insulin-Treated Type 2 Diabetes. Results from the Structured Testing Program (STeP) Study. Abstract P058]

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 10 October, 2010 and appeared in  BG ControlType 2 DiabetesIssue 543

Past five issues: Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 | Issue 790 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Important Advances in Type 1 Diabetes Research
Posted June 25, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Liraglutide Reducing Postprandial Hyperglycemia Using Closed Loop System
Posted June 25, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Would you be interested in a urine test strip product that measures microalbumin and creatinine levels to determine kidney failure risk in your patients?

CME/CE of the Week
Category: Diabetic Foot
CE Credits: .75